These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 35022193)

  • 21. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
    Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
    Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
    Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
    BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.
    Guo Y; Xu X; Wang T; Liu Y; Gu D; Fang Y; Wang Q; Shi H; Wu D; Zhang Z; Zhou G; Ye J
    Int Immunopharmacol; 2024 Sep; 138():112558. PubMed ID: 38941666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).
    Duan H; Shao C; Pan M; Liu H; Dong X; Zhang Y; Tong L; Feng Y; Wang Y; Wang L; Newman NB; Sarkaria IS; Reynolds JV; De Cobelli F; Ma Z; Jiang T; Yan X
    Front Immunol; 2022; 13():849984. PubMed ID: 35720388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
    J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
    Yang G; Su X; Yang H; Luo G; Gao C; Zheng Y; Xie W; Huang M; Bei T; Bai Y; Wang Z; Cai P; He H; Xiang J; Cai M; Zhang Y; Qu C; Fu J; Liu Q; Hu Y; Zhong J; Huang Y; Guo Q; Zhang X
    Ann Transl Med; 2021 Aug; 9(15):1254. PubMed ID: 34532391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
    Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
    Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 31. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
    Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
    BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.
    Kang NN; Zheng H; Hu JX; Cui K; Si PP; Ge W
    Kaohsiung J Med Sci; 2024 Mar; 40(3):291-295. PubMed ID: 38088519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma.
    Wang Z; Chen X; Li Y; Qin J; Fang Y; Yang Z; Fang Y; Qu D; Zhang R; Zheng Q; Kang X; Xue L; Huang J; Li Y; He J
    J Natl Cancer Cent; 2022 Jun; 2(2):98-105. PubMed ID: 39034958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.
    Yin J; Yuan J; Li Y; Fang Y; Wang R; Jiao H; Tang H; Zhang S; Lin S; Su F; Gu J; Jiang T; Lin D; Huang Z; Du C; Wu K; Tan L; Zhou Q
    Nat Med; 2023 Aug; 29(8):2068-2078. PubMed ID: 37488287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
    Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
    Front Immunol; 2021; 12():772450. PubMed ID: 34938292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.
    Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S
    Front Immunol; 2022; 13():953229. PubMed ID: 35911723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
    Chen YY; Wang PP; Hu Y; Yuan Y; Yang YS; Shi HS; Hao Q; Lin Z; Tian JF; Zheng Y; Liu T; Lin PP; Xu H; Ma XL; Yang L; Ding ZY
    Br J Cancer; 2024 Oct; 131(7):1126-1136. PubMed ID: 39164491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
    Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
    Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian T; Liu D; Cao G; Chen Z; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.